eMedicine Specialties > Pediatrics: Cardiac Disease and Critical Care Medicine > Neonatology

Respiratory Distress Syndrome: Multimedia

Author: Arun K Pramanik, MD, MBBS, Professor of Pediatrics, Director of Neonatal Fellowship, Louisiana State University Health Sciences Center
Contributor Information and Disclosures

Updated: Sep 23, 2009

Multimedia

Bottom curve reflects findings from lungs obtaine...
(Enlarge Image)
Media file 1: Bottom curve reflects findings from lungs obtained at postmortem from an infant with hyaline membrane disease (HMD). Lungs with HMD require far more pressure than to achieve a given volume of inflation than do lungs obtained from an infant dying of a nonrespiratory cause. Arrows indicate inspiratory and expiratory limbs of the pressure-volume curves. Note the decreased lung compliance and increased critical opening and closing pressures, respectively, in the premature infant with HMD.
[ CLOSE WINDOW ]
Bottom curve reflects findings from lungs obtaine...

Bottom curve reflects findings from lungs obtained at postmortem from an infant with hyaline membrane disease (HMD). Lungs with HMD require far more pressure than to achieve a given volume of inflation than do lungs obtained from an infant dying of a nonrespiratory cause. Arrows indicate inspiratory and expiratory limbs of the pressure-volume curves. Note the decreased lung compliance and increased critical opening and closing pressures, respectively, in the premature infant with HMD.

Microscopic appearance of lungs of an infant with...
(Enlarge Image)
Media file 2: Microscopic appearance of lungs of an infant with respiratory distress syndrome. Hematoxylin and eosin stain shows hyaline membranes (pink areas).
[ CLOSE WINDOW ]
Microscopic appearance of lungs of an infant with...

Microscopic appearance of lungs of an infant with respiratory distress syndrome. Hematoxylin and eosin stain shows hyaline membranes (pink areas).

Schematic outlines the pathology of respiratory d...
(Enlarge Image)
Media file 3: Schematic outlines the pathology of respiratory distress syndrome (RDS). Infants may recover completely or develop chronic lung damage, resulting in bronchopulmonary dysplasia (BPD). FiO2 = fraction of inspired oxygen; HMD = hyaline membrane disease; V/Q = ventilation perfusion.
[ CLOSE WINDOW ]
Schematic outlines the pathology of respiratory d...

Schematic outlines the pathology of respiratory distress syndrome (RDS). Infants may recover completely or develop chronic lung damage, resulting in bronchopulmonary dysplasia (BPD). FiO2 = fraction of inspired oxygen; HMD = hyaline membrane disease; V/Q = ventilation perfusion.

Bar chart demonstrates the composition of lung su...
(Enlarge Image)
Media file 4: Bar chart demonstrates the composition of lung surfactant. About 1% of the 10% protein component comprises surfactant apoproteins; the remaining proteins are derived from alveolar exudate.
[ CLOSE WINDOW ]
Bar chart demonstrates the composition of lung su...

Bar chart demonstrates the composition of lung surfactant. About 1% of the 10% protein component comprises surfactant apoproteins; the remaining proteins are derived from alveolar exudate.

Schematic show surfactant metabolism, with a sing...
(Enlarge Image)
Media file 5: Schematic show surfactant metabolism, with a single alveolus is shown and the location and movement of surfactant components. Surfactant components are synthesized from precursors in the endoplasmic reticulum and transported through the Golgi apparatus by multivesicular bodies. Components are ultimately packaged in lamellar bodies, which are intracellular storage granules for surfactant before its secretion.

After secretion (exocytosis) into the liquid lining of the alveolus, surfactant phospholipids are organized into a complex lattice called tubular myelin. Tubular myelin is believed to generate the phospholipid that provides material for a monolayer at the air-liquid interface in the alveolus, which lowers surface tension. Surfactant phospholipids and proteins are subsequently taken back into type II cells, possibly in the form of small vesicles, apparently by a specific pathway that involves endosomes, and probably transported for storage into lamellar bodies for recycling.

Alveolar macrophages also take up some surfactant in the liquid layer. A single transit of the phospholipid components of surfactant through the alveolar lumen normally requires a few hours. The phospholipid in the lumen is taken back into type II cell and is reused 10 times before being degraded. Surfactant proteins are synthesized in polyribosomes and extensively modified in the endoplasmic reticulum, Golgi apparatus, and multivesicular bodies. Surfactant proteins are detected in lamellar bodies or secretory vesicles closely associated with lamellar bodies before they are secreted into the alveolus.
[ CLOSE WINDOW ]
Schematic show surfactant metabolism, with a sing...

Schematic show surfactant metabolism, with a single alveolus is shown and the location and movement of surfactant components. Surfactant components are synthesized from precursors in the endoplasmic reticulum and transported through the Golgi apparatus by multivesicular bodies. Components are ultimately packaged in lamellar bodies, which are intracellular storage granules for surfactant before its secretion.

After secretion (exocytosis) into the liquid lining of the alveolus, surfactant phospholipids are organized into a complex lattice called tubular myelin. Tubular myelin is believed to generate the phospholipid that provides material for a monolayer at the air-liquid interface in the alveolus, which lowers surface tension. Surfactant phospholipids and proteins are subsequently taken back into type II cells, possibly in the form of small vesicles, apparently by a specific pathway that involves endosomes, and probably transported for storage into lamellar bodies for recycling.

Alveolar macrophages also take up some surfactant in the liquid layer. A single transit of the phospholipid components of surfactant through the alveolar lumen normally requires a few hours. The phospholipid in the lumen is taken back into type II cell and is reused 10 times before being degraded. Surfactant proteins are synthesized in polyribosomes and extensively modified in the endoplasmic reticulum, Golgi apparatus, and multivesicular bodies. Surfactant proteins are detected in lamellar bodies or secretory vesicles closely associated with lamellar bodies before they are secreted into the alveolus.

Chest radiographs in a premature infant with resp...
(Enlarge Image)
Media file 6: Chest radiographs in a premature infant with respiratory distress syndrome before and after surfactant treatment. Left: Initial radiograph shows poor lung expansion, air bronchogram, and reticular granular appearance. Right: Repeat chest radiograph obtained when the neonate is aged 3 hours and after surfactant therapy demonstrates marked improvement.
[ CLOSE WINDOW ]
Chest radiographs in a premature infant with resp...

Chest radiographs in a premature infant with respiratory distress syndrome before and after surfactant treatment. Left: Initial radiograph shows poor lung expansion, air bronchogram, and reticular granular appearance. Right: Repeat chest radiograph obtained when the neonate is aged 3 hours and after surfactant therapy demonstrates marked improvement.

Effects of early treatment with low-dose inhaled ...
(Enlarge Image)
Media file 7: Effects of early treatment with low-dose inhaled nitric oxide (iNO) on brain injury (ie, grade 3-4 intracranial hemorrhage [ICH], periventricular leukomalacia [PVL], ventriculomegaly) in premature infants according to birth weight strata. iNO reduced ultrasonography findings of brain injury for the overall group (n = 793), with the largest effect in the 750-g to 999-g group (n = 280). Control = □; iNO = ■.
[ CLOSE WINDOW ]
Effects of early treatment with low-dose inhaled ...

Effects of early treatment with low-dose inhaled nitric oxide (iNO) on brain injury (ie, grade 3-4 intracranial hemorrhage [ICH], periventricular leukomalacia [PVL], ventriculomegaly) in premature infants according to birth weight strata. iNO reduced ultrasonography findings of brain injury for the overall group (n = 793), with the largest effect in the 750-g to 999-g group (n = 280). Control = □; iNO = ■.

Effects of early treatment of preterm infants wit...
(Enlarge Image)
Media file 8: Effects of early treatment of preterm infants with low-dose inhaled nitric oxide (iNO) on bronchopulmonary dysplasia (BPD) incidence by birth weight strata. No difference in reduction was reported in infants weighing less than 1000 g (n = 129). Control = □; iNO = ■.
[ CLOSE WINDOW ]
Effects of early treatment of preterm infants wit...

Effects of early treatment of preterm infants with low-dose inhaled nitric oxide (iNO) on bronchopulmonary dysplasia (BPD) incidence by birth weight strata. No difference in reduction was reported in infants weighing less than 1000 g (n = 129). Control = □; iNO = ■.

Effects of inhaled nitric oxide (iNO) survival wi...
(Enlarge Image)
Media file 9: Effects of inhaled nitric oxide (iNO) survival without bronchopulmonary dysplasia (BPD) for infants aged 7-21 days. iNO increased survival without BPD in infants who were treated before age 14 days (n = 727).
[ CLOSE WINDOW ]
Effects of inhaled nitric oxide (iNO) survival wi...

Effects of inhaled nitric oxide (iNO) survival without bronchopulmonary dysplasia (BPD) for infants aged 7-21 days. iNO increased survival without BPD in infants who were treated before age 14 days (n = 727).

More on Respiratory Distress Syndrome

Overview: Respiratory Distress Syndrome
Differential Diagnoses & Workup: Respiratory Distress Syndrome
Treatment & Medication: Respiratory Distress Syndrome
Follow-up: Respiratory Distress Syndrome
Multimedia: Respiratory Distress Syndrome
References
[ CLOSE WINDOW ]

References

  1. [Best Evidence] Hintz SR, Van Meurs KP, Perritt R, et al. Neurodevelopmental Outcomes of Premature Infants with Severe Respiratory Failure Enrolled in a Randomized Controlled Trial of Inhaled Nitric Oxide. Journal of Pediatrics. July 2007;151:e1-3. [Medline].

  2. Billman GF, Hughes AB, Dudell GG, et al. Clinical performance of an in-line, ex vivo point-of-care monitor: a multicenter study. Clin Chem. Nov 2002;48(11):2030-43. [Medline].

  3. Murphy KE, Hannah ME, Willan AR, et al. Multiple courses of antenatal corticosteroids for preterm birth (MACS): a randomised controlled trial. Lancet. Dec 2008;372:2143-2151. [Medline].

  4. Wapner RJ, Sorokin Y, Mele L, et al. Long-term outcomes after repeat doses of antenatal corticosteroids. New England Journal of Medicine. 2007;357:1190-1198. [Medline].

  5. Crowther CA, Doyle LW, Haslam RR, et al. Outcomes at 2 years of age after repeat doses of antenatal corticosteroids. N Engl J Med. 2007;357:1179-1189. [Medline].

  6. Gupta S, Sinha S, Tin W, et al. A randomized controlled trial of post-extubation bubble continuous positive airway pressure versus Infant Flow Driver continuous positive airway pressure in preterm infants with respiratory distress syndrome. Journal of Pediatrics. May 2009;154:645-650. [Medline].

  7. [Best Evidence] De Paoli AG, Davis PG, Faber B, Morley CJ. Devices and Pressure Sources for Administration of Nasal Continuous Positive Airway Pressure (NCPAP) in Preterm Neonates (Review). The Cochrane Collaboration. [Medline].

  8. Stevens TP, Blennow M, Soll RF. Early surfactant administration with brief ventilation vs selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev. 2004;CD003063. [Medline].

  9. Kinniry P, Pick J, Stephens S, et al. KL4-Surfactant Prevents Hyperoxic and LPS-Induced Lung Injury in Mice. Pediatric Pulmonology. October 2006;41:916-928. [Medline].

  10. Moya FR, Gadzinowski J, Bancalari E, Salinas V, Kopelman B, Bancalari A. A multicenter, randomized, masked, comparison trial of lucinactant, colfosceril palmitate, and beractant for the prevention of respiratory distress syndrome among very preterm infants. Pediatrics. Apr 2005;115(4):1018-29. [Medline].

  11. Notter RH. Lung surfactants: Basic science and clinical applications. In: Lung Biology in Health and Disease. Vol 149. 2000:7-344.

  12. Kresch MJ, Lin WH, Thrall RS. Surfactant replacement therapy. Thorax. Nov 1996;51(11):1137-54. [Medline].

  13. Gregory GA, Kitterman JA, Phibbs RH, et al. Treatment of the idiopathic respiratory-distress syndrome with continuous positive airway pressure. N Engl J Med. Jun 17 1971;284(24):1333-40. [Medline].

  14. Subramaniam P, Henderson-Smart DJ, Davis PG. Prophylactic nasal continuous positive airways pressure for preventing morbidity and mortality in very preterm infants. Cochrane Database Syst Rev. July 2005;20:CD001243. [Medline].

  15. Booth C, Premkumar MH, Yannoulis A, et al. Sustainable use of continuous positive airway pressure in extremely preterm infants during the first week after delivery. Arch Dis Child Fetal Neonatal Ed. Nov 2006;91:398-402. [Medline].

  16. Morley CJ, Davis PG, Doyle LW, et al. Nasal CPAP or intubation at birth for very preterm infants. New England Journal of Medicine. Feb 2008;358:700-708. [Medline].

  17. Pillow JJ, Hillman N, Moss TJ, et al. Bubble continuous positive airway pressure enhances lung volume and gas exchange in preterm lambs. Am J Respir Crit Care Med. Jul 1 2007;176(1):63-9. [Medline].

  18. Narendran V, Donovan E, Hoath S, et al. Early Bubble CPAP and Outcomes in ELBW Preterm Infants. Journal of Perinatology. May 2003;23:195-199. [Medline].

  19. Armfield M, West G. Use of Vapotherm for respiratory support with neonates. Paediatr Nurs. Feb 2009;21(1):27-30. [Medline].

  20. Kirby R, Robison E, Schulz J, DeLemos RA. Continuous-flow ventilation as an alternative to assisted or controlled ventilation in infants. Anesth Analg. Nov-Dec 1972;51(6):871-5. [Medline].

  21. Kinsella JP, Abman SH. Inhaled nitric oxide in the premature newborn. J Pediatr. Jul 2007;151(1):10-5. [Medline].

  22. Schreiber MD, Marks JD. No definitive recommendation for iNO in preterm infants. J Pediatr. Jul 2006;149(1):146-7; author reply 147. [Medline].

  23. Van Meurs KP, Hintz SR, Ehrenkranz RA, et al. Inhaled nitric oxide in infants >1500 g and <34 weeks gestation with severe respiratory failure. J Perinatol. Jun 2007;27(6):347-52. [Medline].

  24. Ballard RA, Truog WE, Cnaan A, et al. Inhaled Nitric Oxide in Preterm Infants Undergoing Mechanical Ventilation. New England Journal of Medicine. July 2006;355:343-353. [Medline].

  25. Kinsella JP. Inhaled nitric oxide in the term newborn. Early Hum Dev. Nov 2008;84(11):709-16. [Medline].

  26. Ablow RC, Driscoll SG, Effmann EL, et al. A comparison of early-onset group B streptococcal neonatal infection and the respiratory-distress syndrome of the newborn. N Engl J Med. Jan 8 1976;294(2):65-70. [Medline].

  27. Adamkin DH. Issues in the nutritional support of the ventilated baby. Clin Perinatol. Mar 1998;25(1):79-96. [Medline].

  28. American Academy of Pediatrics Committee on Fetus and Newborn. Surfactant replacement therapy for respiratory distress syndrome. Pediatrics. Mar 1999;103(3):684-5. [Medline].

  29. Ammari A, Suri M, Milisavljevic V, et al. Variables associated with the early failure of nasal CPAP in very low birth weight infants. J Pediatr. Sep 2005;147(3):341-7. [Medline].

  30. Ammari AN, Schulze KF. Uses and abuses of sodium bicarbonate in the neonatal intensive care unit. Curr Opin Pediatr. Apr 2002;14(2):151-6. [Medline].

  31. Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. AMA J Dis Child. May 1959;97(5, Part 1):517-23. [Medline].

  32. Bancalari E, Claure N, Sosenko IR. Bronchopulmonary dysplasia: changes in pathogenesis, epidemiology and definition. Seminars in Neonatology. Feburary 2003;8:63-71. [Medline].

  33. Been JV, Zimmermann LJI. What's New in Surfactant?. European Journal of Pediatrics. 2007;166:889-899. [Medline].

  34. Calvert S. Prophylactic high-frequency oscillatory ventilation in preterm infants. Acta Paediatr Suppl. 2002;91(437):16-8. [Medline].

  35. Cambonie G, Guillaumont S, Luc F, et al. Haemodynamic features during high-frequency oscillatory ventilation in preterms. Acta Paediatr. Sep 2003;92(9):1068-73. [Medline].

  36. Clark RH, Gerstmann DR. Controversies in high-frequency ventilation. Clin Perinatol. Mar 1998;25(1):113-22. [Medline].

  37. Clyman RI, Jobe A, Heymann M, et al. Increased shunt through the patent ductus arteriosus after surfactant replacement therapy. J Pediatr. Jan 1982;100(1):101-7. [Medline].

  38. Cochrane CG. Pulmonary surfactant in allergic inflammation: new insights into the molecular mechanisms of surfactant function. Am J Physiol Lung Cell Mol Physiol. Apr 2005;288(4):L608-9. [Medline].

  39. Courtney SE, Durand DJ, Asselin JM, et al. High-frequency oscillatory ventilation versus conventional mechanical ventilation for very-low-birth-weight infants. N Engl J Med. Aug 29 2002;347(9):643-52. [Medline].

  40. Crowther CA, Harding J. Repeat doses of prenatal corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease. Cochrane Database Syst Rev. 2003;CD003935. [Medline].

  41. Crowther CA, Haslam RR, Hiller JE, et al. Neonatal respiratory distress syndrome after repeat exposure to antenatal corticosteroids: a randomised controlled trial. Lancet. June 2006;367:1913-1919. [Medline].

  42. [Best Evidence] D'Angio CT, Chess PR, Kovacs SJ, et al. Pressure-regulated volume control ventilation vs synchronized intermittent mandatory ventilation for very low-birth-weight infants: a randomized controlled trial. Arch Pediatr Adolesc Med. Sep 2005;159(9):868-75. [Medline].

  43. Desandes R, Desandes E, Droulle P, et al. Inhaled nitric oxide improves oxygenation in very premature infants with low pulmonary blood flow. Acta Paediatr. Jan 2004;93(1):66-9. [Medline].

  44. Dimitriou G, Greenough A, Kavvadia V, et al. Elective use of nasal continuous positive airways pressure following extubation of preterm infants. Eur J Pediatr. June 2000;159:434-439. [Medline].

  45. Donn SM, Sinha SK. Controversies in patient-triggered ventilation. Clin Perinatol. Mar 1998;25(1):49-61. [Medline].

  46. [Best Evidence] Doyle LW, Davis PG, Morley CJ, et al. Outcome at 2 Years of Age of Infants from the DART Study: A Multicenter, International, Randomized, Controlled Trial of Low-Dose Dexamethasonef. Pediatrics. April 2007;119:716-721. [Medline].

  47. Engle WA, The Committee on Fetus and Newborn. Surfactant-Replacement Therapy for Respiratory Distress in the Preterm and Term Neonate. Pediatrics. February 2008;212:419-432. [Medline].

  48. Escobedo MB, Gunkel JH, Kennedy KA, et al. Early surfactant for neonates with mild to moderate respiratory distress syndrome: a multicenter, randomized trial. J Pediatr. Jun 2004;144(6):804-8. [Medline].

  49. Fanaroff AA, Stoll BJ, Wright LL, et al. Trends in Neonatal Morbidity and Mortality for Very Low Birthweight Infants. American Journal of Obstetrics and Gynecology. February 2007;147:e1-e8. [Medline].

  50. Field D, Elbourne D, Truesdale A, et al. Neonatal Ventilation With Inhaled Nitric Oxide Versus Ventilatory Support Without Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure: the INNOVO multicentre randomised controlled trial. Pediatrics. April 2005;115:926-936. [Medline].

  51. Fletcher MA, MacDonald MG, eds. Atlas of Procedures in Neonatology. 2nd ed. Philadelphia, PA: JB Lippincott; 1993.

  52. Fujiwara T, Maeta H, Chida S, et al. Artificial surfactant therapy in hyaline-membrane disease. Lancet. Jan 12 1980;1(8159):55-9. [Medline].

  53. Gannon CM, Wiswell TE, Spitzer AR. Volutrauma, PaCO2 levels, and neurodevelopmental sequelae following assisted ventilation. Clin Perinatol. Mar 1998;25(1):159-75. [Medline].

  54. Garland J, Buck R, Weinberg M. Pulmonary hemorrhage risk in infants with a clinically diagnosed patent ductus arteriosus: a retrospective cohort study. Pediatrics. Nov 1994;94(5):719-23. [Medline].

  55. Gerten KA, Coonrod DV, Bay RC, et al. Cesarean delivery and respiratory distress syndrome: does labor make a difference?. Am J Obstet Gynecol. Sep 2005;193(3 Pt 2):1061-4. [Medline].

  56. Gribetz I, Frank NR, Avery ME. Static volume-pressure relations of excised lungs of infants with hyaline membrane disease, newborn and stillborn infants. J Clin Invest. Dec 1959;38:2168-75. [Medline].

  57. Halliday HL, Ehrenkranz RA. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrance Database Syst Rev. 2001;CD001146:[Medline].

  58. Hallman M, Teramo K. Measurement of the lecithin/sphingomyelin ratio and phosphatidylglycerol in aminotic fluid: an accurate method for the assessment of fetal lung maturity. Br J Obstet Gynaecol. Aug 1981;88(8):806-13. [Medline].

  59. Hamvas A, Cole FS, deMello DE, et al. Surfactant protein B deficiency: antenatal diagnosis and prospective treatment with surfactant replacement. J Pediatr. Sep 1994;125(3):356-61. [Medline].

  60. Hansen BM, Hoff B, Greisen G, et al. Early nasal continuous positive airway pressure in a cohort of the smallest infants in Denmark: neurodevelopmental outcome at five years of age. Acta Paediatr. Feburary 2004;93:190-195. [Medline].

  61. Harris TR, Wood BR. Physiology and principles. In: Goldsmith JP, Karotkin EH, eds. Assisted Ventilation of the Neonate. 3rd ed. Philadelphia, PA: WB Saunders; 1996:48.

  62. Hawgood S. Surfactant protein B: structure and function. Biol Neonate. 2004;85(4):285-9. [Medline].

  63. Hawgood S, Clements JA. Pulmonary surfactant and its apoproteins. J Clin Invest. Jul 1990;86(1):1-6. [Medline].

  64. Holleman-Duray D, Kaupie D, Weiss MG. Heated humidified high-flow nasal cannula: use and a neonatal early extubation protocol. Journal of Perinatology. 2007;27:776-781. [Medline].

  65. Horbar JD, Carpenter JH, Buzas J, et al. Timing of initial surfactant treatment for infants 23 to 29 weeks' gestation: is routine practice evidence based?. Pediatrics. Jun 2004;113(6):1593-602. [Medline].

  66. Jobe AH, Ikegami M. Surfactant metabolism. Clin Perinatol. Dec 1993;20(4):683-96. [Medline].

  67. Jobe AH, Mitchell BR, Gunkel JH. Beneficial effects of the combined use of prenatal corticosteroids and postnatal surfactant on preterm infants. Am J Obstet Gynecol. Feb 1993;168(2):508-13. [Medline].

  68. Johansson J, Some M, Linderholm BM, et al. A synthetic surfactant based on a poly-Leu SP-C analog and phospholipids: effects on tidal volumes and lung gas volumes in ventilated immature newborn rabbits. J Appl Physiol. Nov 2003;95(5):2055-63. [Medline].

  69. Kahn DJ, Courtney SE, Steele AM, Habib RH. Unpredictability of delivered bubble nasal continuous positive airway pressure: role of bias flow magnitude and nares-prong air leaks. Pediatr Res. Sept 2007;62:343-347. [Medline].

  70. Katz LA, Klein JM. Repeat Surfactant Therapy fro Postsurfactant Slump. Journal of Perinatology. May 2006;26:414-422. [Medline].

  71. Koivisto M, Marttila R, Kurkinen-Raty M, et al. Changing incidence and outcome of infants with respiratory distress syndrome in the 1990s: a population-based survey. Acta Paediatr. Feb 2004;93(2):177-84. [Medline].

  72. Laughon M, Bose C, Moya F, et al. A Pilot Randomized, Controlled Trial of Later Treatment With a Peptide-Containing, Synthetic Surfactant for the Prevention of Bronchopulmonary Dysplasia. Pediatrics. 2009;123:89-96. [Medline].

  73. Leipala JA, Iwasaki S, Milner A, Greenough A. Accuracy of the volume and pressure displays of high frequency oscillators. Arch Dis Child Fetal Neonatal Ed. Mar 2004;89(2):F174-6. [Medline].

  74. Lin YJ, Lin CH, Wu JM, et al. The effects of early postnatal dexamethasone therapy on pulmonary outcome in premature infants with respiratory distress syndrome: a two-year follow-up study. Acta Paediatr. Mar 2005;94(3):310-6. [Medline].

  75. Malloy CA, Nicoski P, Muraskas JK. A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. Acta Paediatr. Jun 2005;94(6):779-84. [Medline].

  76. Marttila R, Kaprio J, Hallman M. Respiratory distress syndrome in twin infants compared with singletons. Am J Obstet Gynecol. Jul 2004;191(1):271-6. [Medline].

  77. McGettigan MC, Adolph VR, Ginsberg HG, Goldsmith JP. New ways to ventilate newborns in acute respiratory failure. Pediatr Clin North Am. Jun 1998;45(3):475-509. [Medline].

  78. Molloy EJ. Possible Sequelae of Sustained Lung Inflation in Resuscitation of Preterm Infants. Pediatrics. November 2007;120:1221-1222. [Medline].

  79. Moya F, Maturana A. Animal-Derived Surfactants Versus Past and Current Synthetic Surfactants: Current Status. Clinics in Perinatoloty. 2007;34:145-177. [Medline].

  80. Moya F, Sinha S, Gadzinowski J, et al. One-Year Follow-up of Very Preterm Infants who Received Lucinactant for Prevention of Respiratory Distress Syndrome: Results From 2 Multicenter Randomized, Controlled Trials. Pediatrics. June 2007;119:e1361-e1370. [Medline].

  81. Murray PG, Stewart MJ. Use of Nasal Continuous Positive Airway Pressure During Retrieval of Neonates With Acute Respiratory Distress. Pediatrics. March 2008;121:e754-e758. [Medline].

  82. Nogee LM, de Mello DE, Dehner LP, Colten HR. Brief report: deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis. N Engl J Med. Feb 11 1993;328(6):406-10. [Medline].

  83. Nogee LM, Dunbar AE, Wert S, et al. Mutations in the surfactant protein C gene associated with interstitial lung disease. Chest. Mar 2002;121(3 Suppl):20S-21S. [Medline].

  84. Nogee LM, Garnier G, Dietz HC, et al. A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds. J Clin Invest. Apr 1994;93(4):1860-3. [Medline].

  85. Nogee LM, Wert SE, Proffit SA, et al. Allelic heterogeneity in hereditary surfactant protein B (SP-B) deficiency. Am J Respir Crit Care Med. Mar 2000;161(3 Pt 1):973-81. [Medline].

  86. Ohlsson A, Walia R, Shah S. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrance Database Syst Rev. Jan 2008;23:CD003481. [Medline].

  87. OSIRIS Collaborative Group. Early versus delayed neonatal administration of a synthetic surfactant-- the judgment of OSIRIS. The OSIRIS Collaborative Group (open study of infants at high risk of or with respiratory insufficiency--the role of surfactant. Lancet. Dec 5 1992;340(8832):1363-9. [Medline].

  88. Parvin CA, Kaplan LA, Chapman JF, et al. Predicting respiratory distress syndrome using gestational age and fetal lung maturity by fluorescent polarization. [published correction appears in Am J Obstet Gynecol 2005 Apr;192(4):1354.]. Am J Obstet Gynecol. Jan 2005;192(1):199-207. [Medline].

  89. Peaceman AM, Bajaj K, Kumar P, et al. The interval between a single course of antenatal steroids and delivery and its association with neonatal outcomes. Am J Obstet Gynecol. Sep 2005;193(3 Pt 2):1165-9. [Medline].

  90. Pesonen AK, Raikkonen K, Lano A, et al. Antenatal betamethasone and fetal growth in prematurely born children: implications for temperament traits at the age of 2 years. Pediatrics. Jan 2009;123(1):e31-7. [Medline].

  91. [Best Evidence] Pfister RH, Soll R, Wiswell TE. Protein Containing Synthetic Surfactant Versus Animal-Derived Surfactant Extract for the Prevention and Treatment of Respiratory Distress Syndrome (Review). The Cochrance Collaboration. October 2007;4:[Medline].

  92. Pfister RH, Soll RF. New synthetic surfactants: the next generation?. Biol Neonate. 2005;87(4):338-44. [Medline].

  93. Pramanik AK, Holtzman RB, Merritt TA. Surfactant replacement therapy for pulmonary diseases. Pediatr Clin North Am. Oct 1993;40(5):913-36. [Medline].

  94. Qiu X, Lee SK, Tan K, et al. Comparison of Singleton and Multiple-Birth Outcomes of Infants Born at or Before 32 Weeks Gestation. Obstetrics and Gynecology. February 2008;111:365-371. [Medline].

  95. Reininger A, Khalak R, Kendig JW, et al. Surfactant administration by transient intubation in infants 29 to 35 weeks' gestation with respiratory distress syndrome decreases the likelihood of later mechanical ventilation: a randomized controlled trial. J Perinatol. Nov 2005;25(11):703-8. [Medline].

  96. Ring AM, Garland JS, Stafeil BR, et al. The effect of a prolonged time interval between antenatal corticosteroid administration and delivery on outcomes in preterm neonates: a cohort study. Am J Obstet Gynecol. May 2007;196:1-6. [Medline].

  97. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev. July 2006;3:CD004454. [Medline].

  98. Robertson B, Curstedt T, Tubman R, et al. A 2-year follow up of babies enrolled in a European multicentre trial of porcine surfactant replacement for severe neonatal respiratory distress syndrome. Collaborative European Multicentre Study Group. Eur J Pediatr. May 1992;151(5):372-6. [Medline].

  99. Rojas MA, Lozano JM, Rojas MX, Laughon M, Bose CL, Rondon MA, et al. Very early surfactant without mandatory ventilation in premature infants treated with early continuous positive airway pressure: a randomized, controlled trial. Pediatrics. Jan 2009;123(1):137-42. [Medline].

  100. [Guideline] Royal College of Obstetricians and Gynaecologists (RCOG). Antenatal corticosteroids to prevent respiratory distress syndrome. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG); 2004 Feb.

  101. Sandri F, Ancora G, Lanzoni A, et al. Prophylactic nasal continuous positive airways pressure in newborns of 28-31 weeks gestation: multicentre randomised controlled clinical trial. Arch Dis Child Fetal Neonatal Ed. Sep 2004;89(5):F394-8. [Medline].

  102. Santin R, Brodsky N, Bhandari V. A prospective observational pilot study of synchronized nasal intermittent positive pressure ventilation (SNIPPV) as a primary mode of ventilation in infants > or = 28 weeks with respiratory distress syndrome (RDS). J Perinatol. Aug 2004;24(8):487-93. [Medline].

  103. Schwartz RM, Luby AM, Scanlon JW, Kellogg RJ. Effect of surfactant on morbidity, mortality, and resource use in newborn infants weighing 500 to 1500 g. N Engl J Med. May 26 1994;330(21):1476-80. [Medline].

  104. Serrano AG, Ryan M, Weaver TE, et al. Critical structure-function determinants within the N-terminal region of pulmonary surfactant protein SP-B. Biophys J. Jan 1 2006;90(1):238-49. [Medline].

  105. Seurynck SL, Patch JA, Barron AE. Simple, helical peptoid analogs of lung surfactant protein B. Chem Biol. Jan 2005;12(1):77-88. [Medline].

  106. Shashikant BN, Miller TL, Welch RW, et al. Dose response to rhCC10-augmented surfactant therapy in a lamb model of infant respiratory distress syndrome: physiological, inflammatory, and kinetic profiles. J Appl Physiol. Dec 2005;99(6):2204-11. [Medline].

  107. Shulenin S, Nogee LM, Annilo T, et al. ABCA3 gene mutations in newborns with fatal surfactant deficiency. N Engl J Med. Mar 25 2004;350(13):1296-303. [Medline].

  108. Sinha SK, Gupta S, Donn SM. Immediate Respiratory Management of the Preterm Infant. Seminars in Fetal and Neonatal Medicine. February 2008;13:24-29. [Medline].

  109. Sinha SK, Lacaze-Masmonteil T, Valls i Soler A, et al. A Multicenter, Randomized, Controlled Trial of Lucinactant Versus Poractant Alfa Among Very Premature Infants at High Risk for Respiratory Distress Syndrome. Pediatrics. April 2005;115:1030-1038. [Medline].

  110. Soll RF. Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2000;CD000511. [Medline].

  111. Soll RF. Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2000;CD001079. [Medline].

  112. Soll RF, Blanco F. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev. 2001;CD000144. [Medline].

  113. Soll RF, Morley CJ. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2001;CD000510. [Medline].

  114. Stack JA, Jalaludin B. Developmental Outcomes at the Age of Two Years for Very Premature Babies Managed with Nasal Prong Continuous Positive Airway Pressure. Journal of Paediatrics and Child Health. June 2007;43:480-485. [Medline].

  115. Su PH, Chen JY. Inhaled Nitric Oxide in the Management of Preterm Infants with Severe Respiratory Failure. Journal of Perinatology. February 2008;28:112-116. [Medline].

  116. Suresh GK, Soll RF. Overview of surfactant replacement trials. J Perinatol. May 2005;25 Suppl 2:S40-4. [Medline].

  117. Survanta Multidose Study Group. Two-year follow-up of infants treated for neonatal respiratory distress syndrome with bovine surfactant. J Pediatr. Jun 1994;124(6):962-7. [Medline].

  118. Thomas AQ, Lane K, Phillips J, et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med. May 1 2002;165(9):1322-8. [Medline].

  119. Tooley J, Dyke M. Randomized study of nasal continuous positive airway pressure in the preterm infant with respiratory distress syndrome. Acta Paediatr. Oct 2003;92(10):1170-4. [Medline].

  120. [Best Evidence] Truffert P, Paris-Llado J, Escande B, et al. Neuromotor Outcome at 2 Years of Very Preterm Infants Who Were Treated with High-Frequency Oscillatory Ventilation or Conventional Ventilation for Neonatal Respiratory Distress Syndrome. Pediatrics. 2007;119:e860-e865. [Medline].

  121. Turker G, Koksal N. Complement 4 levels as early predictors of poor response to surfactant therapy in respiratory distress syndrome. Am J Perinatol. Apr 2005;22(3):149-54. [Medline].

  122. Umbilical Artery Catheter Trial Study Group. Relationship of intraventricular hemorrhage or death with the level of umbilical artery catheter placement: a multicenter randomized clinical trial. Pediatrics. Dec 1992;90(6):881-7. [Medline].

  123. Urschitz MS, Horn W, Seyfang A, et al. Automatic control of the inspired oxygen fraction in preterm infants: a randomized crossover trial. Am J Respir Crit Care Med. Nov 15 2004;170(10):1095-100. [Medline].

  124. Verder H, Ebbesen F, Linderholm B, et al. Prediction of respiratory distress syndrome by the microbubble stability test on gastric aspirates in newborns of less than 32 weeks' gestation. Acta Paediatr. Jun 2003;92(6):728-33. [Medline].

  125. Wapner RJ, Sorokin Y, Thom EA, et al. Single versus weekly courses of antenatal corticosteroids: evaluation of safety and efficacy. Am J Obstet Gynecol. 2006;195:633-642. [Medline].

  126. Wax JR, Herson V, Carignan E, et al. Contribution of elective delivery to severe respiratory distress at term. Am J Perinatol. Feb 2002;19(2):81-6. [Medline].

  127. [Best Evidence] Wells DA, Gillies D, Fitzgerald DA. Positioning for acute respiratory distress in hospitalised infants and children. Cochrane Database Syst Rev. 2005;CD003645. [Medline].

  128. Whitsett JA, Pryhuber GS, Rice WR, et al. Acute respiratory disorders in neonatology. In: Avery GB, Fletcher MA, MacDonald MG, eds. Pathophysiology and Management of the Newborn. 5th ed. JB Lippincott; 1999:485.

  129. Whitsett JA, Weaver TE. Hydrophobic surfactant proteins in lung function and disease. N Engl J Med. Dec 26 2002;347(26):2141-8. [Medline].

  130. Whitsett JA, Wert SE, Xu Y. Genetic disorders of surfactant homeostasis. Biol Neonate. 2005;87(4):283-7. [Medline].

  131. Wright JR. Immunoregulatory functions of surfactant proteins. Nat Rev Immunol. Jan 2005;5(1):58-68. [Medline].

  132. Yost CC, Soll RF. Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev. 2000;CD001456. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

respiratory distress syndrome, RDS, HMD, hyaline membrane disease, premature infant, surfactant therapy, mechanical ventilation, continuous positive airway pressure, CPAP, inhaled nitric oxide, patent ductus arteriosus, prematurity, septicemia, bronchopulmonary dysplasia, BPD, necrotizing enterocolitis, NEC, retinopathy of prematurity, ROP, hypertension, failure to thrive, intraventricular hemorrhage, periventricular leukomalacia, group B streptococcus, , influenza virus, adenovirus, respiratory syncytial virus, RSV, metabolic acidosis, chronic lung disease, congenital diaphragmatic hernia, pulmonary hypoplasia, meconium aspiration pneumonia, hypothermia, hypoglycemia, anemia, polycythemia, jaundice, transient tachypnea of newborn, aspiration syndrome, pneumothorax, interstitial emphysema, pneumomediastinum, pneumopericardium, chylothorax, treatment, diagnosis

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Arun K Pramanik, MD, MBBS, Professor of Pediatrics, Director of Neonatal Fellowship, Louisiana State University Health Sciences Center
Arun K Pramanik, MD, MBBS is a member of the following medical societies: American Academy of Pediatrics, American Thoracic Society, National Perinatal Association, and Southern Society for Pediatric Research
Disclosure: Nothing to disclose.

Medical Editor

Steven M Donn, MD, Professor of Pediatrics, University of Michigan Medical School; Director, Division of Neonatal-Perinatal Medicine, Department of Pediatrics, CS Mott Children's Hospital, University of Michigan Health System
Steven M Donn, MD is a member of the following medical societies: American Pediatric Society
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

David A Clark, MD, Chairman, Professor, Department of Pediatrics, Albany Medical College
David A Clark, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Pediatric Society, Christian Medical & Dental Society, Medical Society of the State of New York, New York Academy of Sciences, and Society for Pediatric Research
Disclosure: Nothing to disclose.

CME Editor

Carol L Wagner, MD, Professor of Pediatrics, Medical University of South Carolina
Carol L Wagner, MD is a member of the following medical societies: American Academy of Pediatrics, American Chemical Society, American Medical Women's Association, American Public Health Association, American Society for Bone and Mineral Research, American Society for Clinical Nutrition, Massachusetts Medical Society, National Perinatal Association, and Society for Pediatric Research
Disclosure: Nothing to disclose.

Chief Editor

Ted Rosenkrantz, MD, Professor, Departments of Pediatrics and Obstetrics/Gynecology, Division of Neonatal-Perinatal Medicine, University of Connecticut School of Medicine
Ted Rosenkrantz, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, American Pediatric Society, Connecticut State Medical Society, Eastern Society for Pediatric Research, and Society for Pediatric Research
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.